More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […] June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2019 Cell Encapsulation Biotech Raises €7M to Target Cell Therapy Bottlenecks The French company Treefrog Therapeutics has raised over €7M in Series A investment to develop its encapsulation technology to improve the production of stem cells for cell therapies. Part of the Series A money will help Treefrog to automate its stem cell production process by 2021. The round will also fund the development of a […] May 13, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2018 AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […] November 16, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2018 Parkinson’s Disease Vaccine Shows Preclinical Promise The biotech company United Neuroscience has developed a candidate Parkinson’s disease vaccine that targets a protein linked to the condition. The vaccine teaches the immune system to attack aggregations of alpha-synuclein. When this protein aggregates in neurons, it can lead to several neurodegenerative disorders, including Parkinson’s. In United Neuroscience’s preclinical study, the vaccine was able to prevent the […] November 14, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2018 Parkinson’s Disease Gene Therapy Clinical Trial Launched in UK A gene therapy for Parkinson’s disease developed by Swiss biotech Axovant has been used on the first patient in a Phase I/II trial at University College London. Parkinson’s disease is a neurodegenerative disease, caused by a lack of the neurochemical dopamine in regions of the brain handling motor functions causing debilitating symptoms such as rigidity […] October 25, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2018 Modulating the Microbiome Could Boost Vaccine Performance Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […] August 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Our Eyes Could Open A Window to Diagnosing Alzheimer’s and Parkinson’s Disease Spanish researchers have developed a way to diagnose neurodegenerative diseases by analyzing eye movements. The Madrid-based research team and its spin-off company Aura Innovative Robotics have developed a diagnostic test for neurodegenerative disease that tracks a patient’s eye movements and analyzes the data using machine learning. The diagnostic test, called OSCANN Desk, is currently being […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2018 Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […] May 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 Major $115M Fundraising Fuels AI Drug Development BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […] April 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2018 AI Is Being Put to Work to Treat Parkinson’s Disease in the UK The artificial intelligence company BenevolentAI is collaborating with two UK charities to use AI to identify ideal drug candidates for treating Parkinson’s disease. BenevolentAI, Europe’s largest private AI company, is collaborating with Parkinson’s UK and The Cure Parkinson’s Trust (CPT), two UK charities, to repurpose at least three existing drugs and identify two novel drug targets […] March 28, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2018 Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its pipeline with the acquisition of Prexton Therapeutics. The deal grants Lundbeck with global rights to foliglurax, a drug to reduce the “off” time periods when Parkinson’s motor […] March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email